Opinion: AMR poses a risk to malaria eradication — but how much?

Opinion: AMR poses a risk to malaria eradication — but how much?

Malaria patients being treated with masks during COVID-19

During World Antimicrobial Awareness Week, MMV's Cristina Donini, Senior Director, Head of Program Leadership and Strategy, and Didier Leroy, Senior Director of Drug Discovery, weigh in on how to respond to antimicrobial resistance as part of malaria eradication efforts.

World Antimicrobial Awareness Week from Nov. 18-24 draws attention to the risk that drug resistance poses to global health security. The 2022 theme “Preventing antimicrobial resistance together” focuses on the importance of investment and collaboration to address this threat, which claimed over one million lives in 2019. Recognizing the importance of a coordinated response, the World Health Organization kicked off the week by launching its strategy to respond to antimalarial drug resistance in Africa.

Throughout recent history, the efficacy of malaria medicines has repeatedly been compromised by drug resistance. Progress has been made over the last 20 years in bringing malaria under control through intensified use of a mix of control measures, including insecticide-treated bed nets and artemisinin-based treatments. Today, the utility of these interventions is again under threat.

Read the full article on Devex.